Harel Insurance Investments & Financial Services Ltd. Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 15,000 shares of the company’s stock, valued at approximately $624,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in Moderna during the third quarter worth about $80,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on MRNA. UBS Group lowered their target price on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Piper Sandler reissued an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $75.58.

Moderna Stock Down 2.3 %

Shares of Moderna stock opened at $41.41 on Friday. Moderna, Inc. has a fifty-two week low of $31.94 and a fifty-two week high of $170.47. The firm has a fifty day moving average price of $40.60 and a two-hundred day moving average price of $64.04. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the firm earned ($1.39) EPS. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -9.27 EPS for the current year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.